Related Experiment Video
Updated: Jul 13, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Hormonal replacement therapy (HRT) in postmenopause: a reappraisal
1CHU Saint-Pierre and Laboratory of Physiology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. acfz@ulb.ac.be
Hormone replacement therapy (HRT) is effective for menopausal symptoms. Formulation choice, like transdermal estradiol with micronized progesterone, is key to balancing benefits and risks, especially for cardiovascular health and bone density.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
- Geriatrics
Background:
- Hormone replacement therapy (HRT) is the primary treatment for menopausal symptoms like hot flashes and vaginal dryness.
- Past clinical trials raised concerns about HRT's safety, leading to revised health authority recommendations.
- Adverse effects of HRT are influenced by formulation, dosage, administration route, patient age, and comorbidities.
Purpose of the Study:
- To evaluate the current understanding of hormone replacement therapy's efficacy and safety.
- To analyze how different HRT formulations impact health outcomes in postmenopausal women.
- To provide guidance on optimizing HRT for individual patient needs.
Main Methods:
- Review of experimental and clinical studies on HRT.
- Comparison of various estrogen and progestin formulations and administration routes.
- Analysis of HRT's effects on vasomotor symptoms, bone structure, cardiovascular health, and cancer risk.
Main Results:
- Transdermal estradiol with micronized progesterone shows a favorable risk-benefit profile compared to oral estrogen and certain progestins.
- Transdermal estrogen is associated with lower cardiovascular and breast cancer risks than oral estrogen.
- Micronized progesterone appears safer regarding cardiovascular and breast cancer risks than many progestin compounds.
Conclusions:
- The combination of transdermal estradiol and micronized progesterone is considered a safe and effective HRT option when administered with precautions.
- HRT can be beneficial for preventing bone loss and potentially improving coronary disease in younger postmenopausal women.
- Individualized HRT adjustment, potentially aided by genetic screening, is crucial for maximizing benefits and minimizing risks.
Related Concept Videos
Menopause
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Regulation
Hormonal Regulation
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Bone Remodeling
